Spectral Ai, INC 10-Q quarterly reports

Spectral AI, Inc. announced its Q2 2026 financial results, highlighting FDA De Novo classification for its DeepView System, while revenue declined and net loss widened.

Spectral AI reported a significant increase in net loss for Q3 2025, driven by reduced research and development activities as it nears FDA submission, while bolstering its liquidity with new debt and equity financing.

Spectral AI, Inc. reported a reduced net loss for the second quarter of 2025, driven by decreased operating expenses, while advancing its DeepView System with an FDA De Novo application and securing new financing.

Spectral AI reports increased revenue and a shift to net income positive in Q1 2025, driven by government contracts and strategic financing activities.

Spectral AI's Q3 2024 report shows a significant increase in research and development revenue, driven by government contracts, while the company continues to develop its DeepView System.

Spectral AI's Q2 2024 results show a significant increase in research and development revenue, primarily driven by government contracts, while the company continues to navigate financial challenges.

Spectral AI's first quarter 2024 results show a significant increase in research and development revenue, driven by government contracts, while the company continues to develop its DeepView System.